DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS

The development of the biopharmaceuticals begins with the development of effective producers. But the more complex protein and its producer, the greater the amount of impurities is synthesized or accumulated during the upstream process. Among them are as follows: bacterial endotoxins, viruses, host...

Full description

Saved in:
Bibliographic Details
Main Author: D. A. Gusarov
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2019-01-01
Series:Разработка и регистрация лекарственных средств
Subjects:
Online Access:https://www.pharmjournal.ru/jour/article/view/294
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849696197864849408
author D. A. Gusarov
author_facet D. A. Gusarov
author_sort D. A. Gusarov
collection DOAJ
description The development of the biopharmaceuticals begins with the development of effective producers. But the more complex protein and its producer, the greater the amount of impurities is synthesized or accumulated during the upstream process. Among them are as follows: bacterial endotoxins, viruses, host cell proteins, related impurities, aggregates and high molecular weight admixtures etc. This article describes approaches to the downstream process purification of biopharmaceutical proteins. We discuss the main chromatography and non-chromatographical methods.
format Article
id doaj-art-e209e0bed88642cd9d9619b57f44bda7
institution DOAJ
issn 2305-2066
2658-5049
language Russian
publishDate 2019-01-01
publisher LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
record_format Article
series Разработка и регистрация лекарственных средств
spelling doaj-art-e209e0bed88642cd9d9619b57f44bda72025-08-20T03:19:32ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492019-01-01038899294DOWNSTREAM PROCESS OF BIOPHARMACEUTICALSD. A. Gusarov0R&D and Pilo Plant Biotechnological Platform «ExpertBIOTECH»The development of the biopharmaceuticals begins with the development of effective producers. But the more complex protein and its producer, the greater the amount of impurities is synthesized or accumulated during the upstream process. Among them are as follows: bacterial endotoxins, viruses, host cell proteins, related impurities, aggregates and high molecular weight admixtures etc. This article describes approaches to the downstream process purification of biopharmaceutical proteins. We discuss the main chromatography and non-chromatographical methods.https://www.pharmjournal.ru/jour/article/view/294downstream processpurificationimpurities
spellingShingle D. A. Gusarov
DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
Разработка и регистрация лекарственных средств
downstream process
purification
impurities
title DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
title_full DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
title_fullStr DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
title_full_unstemmed DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
title_short DOWNSTREAM PROCESS OF BIOPHARMACEUTICALS
title_sort downstream process of biopharmaceuticals
topic downstream process
purification
impurities
url https://www.pharmjournal.ru/jour/article/view/294
work_keys_str_mv AT dagusarov downstreamprocessofbiopharmaceuticals